Back to top
more

QuidelOrtho (QDEL)

(Delayed Data from NSDQ)

$42.82 USD

42.82
672,309

-1.17 (-2.66%)

Updated May 17, 2024 04:00 PM ET

After-Market: $42.83 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Swayta Shah headshot

5 Stocks With Solid Sales Growth to Fight Economic Slowdown

by Swayta Shah

Sales growth is vital for the survival of a business, even during an economic slowdown. Let's check Boyd Gaming (BYD), Expeditors International (EXPD), QuidelOrtho (QDEL), LPL Financial (LPLA) and Cboe Global (CBOE), which are recording top-line growth.

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

QuidelOrtho (QDEL) Crossed Above the 20-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Zacks.com featured highlights include Crocs, Unum Group, QuidelOrtho, LPL Financial Holdings and Clean Harbors

by Zacks Equity Research

Crocs, Unum Group, QuidelOrtho, LPL Financial Holdings and Clean Harbors are part of the Zacks Screen of the Week article.

Swayta Shah headshot

5 Stocks With Solid Sales Growth to Navigate Volatile Markets

by Swayta Shah

Sales growth is vital for the survival of a business, even during an economic slowdown. Let's check Crocs (CROX), Unum (UNM), QuidelOrtho (QDEL), LPL Financial (LPLA) and Clean Harbors (CLH), which are witnessing top-line growth.

Indrajit Bandyopadhyay headshot

3 Medical Products Stocks Navigating Industry Challenges (Revised)

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.

Is QuidelOrtho (QDEL) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Industry Outlook Highlights QuidelOrtho, Lantheus and TG Therapeutics

by Zacks Equity Research

QuidelOrtho, Lantheus and TG Therapeutics are part of Zacks Industry Outlook article.

Indrajit Bandyopadhyay headshot

3 Medical Products Stocks Navigating Industry Challenges

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.

Are Investors Undervaluing PetIQ (PETQ) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks.com featured highlights Conagra, Cboe Global Markets, QuidelOrtho, American Electric Power Company and Clean Harbors

by Zacks Equity Research

Conagra, Cboe Global Markets, QuidelOrtho, American Electric Power Company and Clean Harbors have been highlighted in this Screen of The Week article.

Swayta Shah headshot

5 Stocks With Robust Sales Growth to Combat Recession Fears

by Swayta Shah

Sales growth is vital for the survival of a business, even during an economic slowdown. Let's check Conagra Brands (CAG), Cboe Global Markets (CBOE), QuidelOrtho (QDEL), American Electric Power (AEP) & Clean Harbors (CLH) that are recording top-line growth.

QuidelOrtho (QDEL) Q3 Earnings Top Estimates, 2022 View Revised

by Zacks Equity Research

QuidelOrtho's (QDEL) robust results in POC and Donor Screening product lines drives its third-quarter 2022 top line.

Is Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View

by Zacks Equity Research

QuidelOrtho's (QDEL) robust performance across majority of its business units and geographies drives its second-quarter 2022 top line.

QuidelOrtho (QDEL) Q2 Earnings Miss Estimates

by Zacks Equity Research

QuidelOrtho (QDEL) delivered earnings and revenue surprises of -42.55% and 7.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

What's in the Offing for QuidelOrtho (QDEL) in Q2 Earnings?

by Zacks Equity Research

QuidelOrtho's (QDEL) second-quarter results are likely to reflect strength across both its COVID and non-COVID businesses.

Stryker's (SYK) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Bio-Rad's (BIO) Clinical Diagnostics segment is expected to report growth in Q2, driven by its focus on laboratory workflow productivity, quality control, and new opportunities in molecular diagnostics.

Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) S.E.T. arm is expected to deliver strong results on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.

    Lantheus Holdings, Inc. (LNTH) Hit a 52 Week High, Can the Run Continue?

    by Zacks Equity Research

    Lantheus Holdings (LNTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

    LabCorp (LH) to Report Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    LabCorp's (LH) Diagnostics base business organic volume is anticipated to have continued its rally in Q2, led by consistent growth in esoteric and routine procedures.